Cargando…
Npt2a as a target for treating hyperphosphatemia
Hyperphosphatemia results from an imbalance in phosphate (P(i)) homeostasis. In patients with and without reduced kidney function, hyperphosphatemia is associated with cardiovascular complications. The current mainstays in the management of hyperphosphatemia are oral P(i) binder and dietary P(i) res...
Autores principales: | Thomas, Linto, Dominguez Rieg, Jessica A., Rieg, Timo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Portland Press Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9022968/ https://www.ncbi.nlm.nih.gov/pubmed/34994388 http://dx.doi.org/10.1042/BST20211005 |
Ejemplares similares
-
Sodium phosphate cotransporter 2a inhibitors: potential therapeutic uses
por: Xue, Jianxiang, et al.
Publicado: (2022) -
NPT-IIb Inhibition Does Not Improve Hyperphosphatemia in CKD
por: Larsson, Tobias E., et al.
Publicado: (2017) -
Genetic deletion of connexin 37 causes polyuria and polydipsia
por: Xue, Jianxiang, et al.
Publicado: (2020) -
Intestine-Specific NHE3 Deletion in Adulthood Causes Microbial Dysbiosis
por: Xue, Jianxiang, et al.
Publicado: (2022) -
Intravenous ferric carboxymaltose and ferric derisomaltose alter the intestinal microbiome in female iron-deficient anemic mice
por: Rieg, Timo, et al.
Publicado: (2023)